Drug Trial Radar · NCT04157478
Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma
Last checked: Nov 20, 2026Latest source record: Nov 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
464
Planned (sponsor's estimate)
Start
Jan 2020
Primary completion
Dec 2022
Study completion Dec 2024
Sponsor
- Lead sponsor
- People's Hospital of Guangxi Zhuang Autonomous RegionAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- First Affiliated Hospital of Guangxi Medical University; Cancer Hospital of Guangxi Medical University; Liuzhou Workers' Hospital; Nanxishan Hospital; LiuZhou People's Hospital; Affiliated Hospital of Guilin University
- First posted
- Nov 8, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
For patients with glioblastoma,postoperative radiotherapy combined with concurrent and adjuvant temozolomide (Stupp regimen) has long been considered a standard treatment approach.The treatment outcomes, however, are still dismal, with a median overall survival time of 8-12 months. As a novel small molecule multi-target tyrosine kinase inhibitor, anlotinib hydrochloride has been found to be able to inhibit both tumor angiogenesis and cell growth.Previous studies on recurrent glioblastoma have demonstrated its effectiveness in tumor control with manageable toxicities. The current study is designed to evaluate the efficacy and feasibility of the additional anlotinib hydrochloride to the Stupp regimen for newly diagnosed glioblastoma.
Conditions
- Glioblastoma
Interventions
Anlotinib HydrochlorideDrug
Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
Radiation therapyRadiation
Radiation therapy will be delivered in daily fractions of 2 Gy given 5 days a week for a total of 60 Gy.
TemozolomideDrug
Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survivalTime frame: 3 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Nanxishan Hospital of Guangxi Zhuang Autonomous Region
Guilin, Guangxi, China
Liuzhou Worker's Hospital
Liuzhou, Guangxi, China
Liuzhou People's Hospital
Liuzhou, Guangxi, China
Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
Affiliated Tumor Hospital of Guangxi Medical University
Nanning, Guangxi, China
People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China
Yulin First Hospital
Yulin, Guangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.